Gln-AMS |
Catalog No.GC30683
One-Click Copy Product Info
|
Gln-AMS is an aminoacyl-tRNA synthetase (AARS) inhibitor, with the Ki value of 1.32μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 209543-57-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Gln-AMS is an aminoacyl-tRNA synthetase (AARS) inhibitor, with the Ki value of 1.32μM [1]. Gln-AMS inhibits ferroptosis in hyperglycemic cells by simultaneously suppressing the expression of AARS1 and H3K18la [2]. Gln-AMS is widely used as a potent and synergistic immunosuppressant to regulate the allogeneic mixed lymphocyte reaction [3].
In vitro, Gln-AMS (10μM) treatment for 12 hours significantly inhibited the accumulation of Kla in lactate-induced mouse primary hippocampal neurons neuron cells and the lactylation of ATR-interacting protein (ATRIP), as well as the ATR/CHK1 signaling pathway [4].
References:
[1] Rath V L, Silvian L F, Beijer B, et al. How glutaminyl-tRNA synthetase selects glutamine[J]. Structure, 1998, 6(4): 439-449.
[2] Hong J, Xu H, Yu L, et al. AARS1-mediated lactylation of H3K18 and STAT1 promotes ferroptosis in diabetic nephropathy[J]. Cell Death & Differentiation, 2026, 33(3): 589-604.
[3] Van de Vijver P, Ostrowski T, Sproat B, et al. Aminoacyl-tRNA synthetase inhibitors as potent and synergistic immunosuppressants[J]. Journal of medicinal chemistry, 2008, 51(10): 3020-3029.
[4] Luo S, Lyu Z, Huang H, et al. Targeting AARS1-dependent lactylation improves neuronal process plasticity and mitigates cognitive deficits in sepsis-associated encephalopathy[J]. Brain, Behavior, and Immunity, 2026: 106493.
| Cell experiment [1]: | |
|
Cell lines |
Primary hippocampal neuron cells from C57BL/6 neonatal mice |
|
Preparation Method |
Primary hippocampal neurons neuron cells were grown in DMEM medium with 10% (v/v) fetal bovine serum (FBS), 100μg/ml streptomycin, and 100U/ml penicillin at 37°C in 5% CO2/atmosphere. Cells were treated with 2mM lactate for 12h in the presence or absence of Gln-AMS (10μM). Cell viability was evaluated. Use Western blot to analyze the protein expression levels in the cytoplasmic lysate. |
|
Reaction Conditions |
10μM; 12h |
|
Applications |
Gln-AMS treatment significantly suppressed lactate-induced Kla accumulation in primary hippocampal neurons neuron cells. |
|
References: |
|
| Cas No. | 209543-57-7 | SDF | |
| Canonical SMILES | O[C@@H]([C@H]([C@H](N1C=NC2=C1N=CN=C2N)O3)O)[C@H]3COS(=O)(NC([C@@H](N)CCC(N)=O)=O)=O | ||
| Formula | C15H22N8O8S | M.Wt | 474.45 |
| Solubility | DMSO : 120 mg/mL (252.92 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1077 mL | 10.5385 mL | 21.077 mL |
| 5 mM | 421.5 μL | 2.1077 mL | 4.2154 mL |
| 10 mM | 210.8 μL | 1.0539 mL | 2.1077 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)